HomeCompareICAD vs EQR

ICAD vs EQR: Dividend Comparison 2026

ICAD yields 51.68% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICAD wins by $389.1K in total portfolio value
10 years
ICAD
ICAD
● Live price
51.68%
Share price
$3.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$429.5K
Annual income
$89,362.88
Full ICAD calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — ICAD vs EQR

📍 ICAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICADEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICAD + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICAD pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICAD
Annual income on $10K today (after 15% tax)
$4,392.76/yr
After 10yr DRIP, annual income (after tax)
$75,958.45/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, ICAD beats the other by $72,711.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICAD + EQR for your $10,000?

ICAD: 50%EQR: 50%
100% EQR50/50100% ICAD
Portfolio after 10yr
$235.0K
Annual income
$46,591.24/yr
Blended yield
19.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ICAD
Analyst Ratings
8
Buy
2
Hold
Consensus: Buy
Altman Z
-1.9
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICAD buys
0
EQR buys
0
No recent congressional trades found for ICAD or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICADEQR
Forward yield51.68%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$429.5K$40.5K
Annual income after 10y$89,362.88$3,819.61
Total dividends collected$345.3K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: ICAD vs EQR ($10,000, DRIP)

YearICAD PortfolioICAD Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$15,868$5,167.96$11,248$547.57+$4.6KICAD
2$24,643$7,664.01$12,701$666.53+$11.9KICAD
3$37,491$11,123.47$14,405$814.59+$23.1KICAD
4$55,932$15,816.01$16,413$999.84+$39.5KICAD
5$81,898$22,051.65$18,795$1,232.92+$63.1KICAD
6$117,808$30,176.98$21,639$1,527.95+$96.2KICAD
7$166,624$40,568.81$25,057$1,903.80+$141.6KICAD
8$231,913$53,625.26$29,197$2,385.87+$202.7KICAD
9$317,901$69,754.66$34,250$3,008.70+$283.7KICAD
10$429,517$89,362.88$40,467$3,819.61+$389.1KICAD

ICAD vs EQR: Complete Analysis 2026

ICADStock

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Full ICAD Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ICAD vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICAD vs SCHDICAD vs JEPIICAD vs OICAD vs KOICAD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.